These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 19451566)

  • 1. ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction.
    Ezekowitz JA; McAlister FA
    Ann Intern Med; 2009 May; 150(10):JC5-10. PubMed ID: 19451566
    [No Abstract]   [Full Text] [Related]  

  • 2. Trends in prevalence and outcome of heart failure with preserved ejection fraction.
    Owan TE; Hodge DO; Herges RM; Jacobsen SJ; Roger VL; Redfield MM
    N Engl J Med; 2006 Jul; 355(3):251-9. PubMed ID: 16855265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction.
    Alla F; Al-Hindi AY; Lee CR; Schwartz TA; Patterson JH; Adams KF
    Am Heart J; 2007 Jun; 153(6):1074-80. PubMed ID: 17540212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction--a meta analysis of 7 prospective clinical studies.
    Fu M; Zhou J; Sun A; Zhang S; Zhang C; Zou Y; Fu M; Ge J
    Int J Cardiol; 2012 Feb; 155(1):33-8. PubMed ID: 21481482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of heart failure with preserved ejection fraction in a population-based study.
    Bhatia RS; Tu JV; Lee DS; Austin PC; Fang J; Haouzi A; Gong Y; Liu PP
    N Engl J Med; 2006 Jul; 355(3):260-9. PubMed ID: 16855266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
    MacDonald MR; Petrie MC; Varyani F; Ostergren J; Michelson EL; Young JB; Solomon SD; Granger CB; Swedberg K; Yusuf S; Pfeffer MA; McMurray JJ;
    Eur Heart J; 2008 Jun; 29(11):1377-85. PubMed ID: 18413309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACP Journal Club. Telmisartan did not reduce a composite of CV death, MI, HF, or stroke in high-risk patients intolerant to ACE inhibitors.
    Taylor RJ
    Ann Intern Med; 2009 Feb; 150(4):JC2-6. PubMed ID: 19238604
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.
    Solomon SD; Anavekar N; Skali H; McMurray JJ; Swedberg K; Yusuf S; Granger CB; Michelson EL; Wang D; Pocock S; Pfeffer MA;
    Circulation; 2005 Dec; 112(24):3738-44. PubMed ID: 16330684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diastolic heart failure in elderly: the prognostic factors and interventions regarding heart failure with preserved ejection fraction.
    Acikel S; Akdemir R; Kilic H; Yesilay AB; Dogan M; Cagirci G
    Int J Cardiol; 2010 Feb; 138(3):311-3. PubMed ID: 18845346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
    O'Connor CM; Miller AB; Blair JE; Konstam MA; Wedge P; Bahit MC; Carson P; Haass M; Hauptman PJ; Metra M; Oren RM; Patten R; Piña I; Roth S; Sackner-Bernstein JD; Traver B; Cook T; Gheorghiade M;
    Am Heart J; 2010 May; 159(5):841-849.e1. PubMed ID: 20435194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.
    Farkouh M
    Ann Intern Med; 2010 Jun; 152(12):JC6-10. PubMed ID: 20547892
    [No Abstract]   [Full Text] [Related]  

  • 13. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
    O'Meara E; Clayton T; McEntegart MB; McMurray JJ; Piña IL; Granger CB; Ostergren J; Michelson EL; Solomon SD; Pocock S; Yusuf S; Swedberg K; Pfeffer MA;
    Circulation; 2007 Jun; 115(24):3111-20. PubMed ID: 17562950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACP Journal Club. Review: Statins reduce mortality and cardiovascular (CV) morbidity in patients with low CV risk.
    Muñoz D; Granger CB
    Ann Intern Med; 2012 Apr; 156(8):JC4-07. PubMed ID: 22508747
    [No Abstract]   [Full Text] [Related]  

  • 15. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction.
    Akiyama E; Sugiyama S; Matsuzawa Y; Konishi M; Suzuki H; Nozaki T; Ohba K; Matsubara J; Maeda H; Horibata Y; Sakamoto K; Sugamura K; Yamamuro M; Sumida H; Kaikita K; Iwashita S; Matsui K; Kimura K; Umemura S; Ogawa H
    J Am Coll Cardiol; 2012 Oct; 60(18):1778-86. PubMed ID: 23040568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACP Journal Club. Review: Aspirin does not reduce CV events but may reduce nonfatal stroke in peripheral artery disease.
    Mukherjee D
    Ann Intern Med; 2009 Sep; 151(6):JC3-5, JC3-4. PubMed ID: 19755351
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
    Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
    Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACP Journal Club: Review: Low BP targets do not reduce mortality or CV events in hypertension.
    McAlister FA
    Ann Intern Med; 2009 Nov; 151(10):JC5-6-7. PubMed ID: 19920264
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF).
    Yamamoto K; Origasa H; Hori M;
    Eur J Heart Fail; 2013 Jan; 15(1):110-8. PubMed ID: 22983988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.